These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1123 related articles for article (PubMed ID: 10997396)
1. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396 [TBL] [Abstract][Full Text] [Related]
2. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. Bisset LR; Cone RW; Huber W; Battegay M; Vernazza PL; Weber R; Grob PJ; Opravil M AIDS; 1998 Nov; 12(16):2115-23. PubMed ID: 9833852 [TBL] [Abstract][Full Text] [Related]
3. Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study. Bürgisser P; Hammann C; Kaufmann D; Battegay M; Rutschmann OT Clin Exp Immunol; 1999 Mar; 115(3):458-63. PubMed ID: 10193418 [TBL] [Abstract][Full Text] [Related]
4. Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors. Plana M; Martínez C; García F; Maleno MJ; Barceló JJ; García A; Lejeune M; Vidal C; Cruceta A; Miró JM; Pumarola T; Gallart T; Gatell JM J Acquir Immune Defic Syndr; 2002 Apr; 29(5):429-34. PubMed ID: 11981357 [TBL] [Abstract][Full Text] [Related]
5. Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection. Dyrhol-Riise AM; Voltersvik P; Olofsson J; Asjö B AIDS; 1999 Dec; 13(17):2365-76. PubMed ID: 10597778 [TBL] [Abstract][Full Text] [Related]
6. Association of CD8+ T lymphocyte subsets with the most commonly used markers to monitor HIV type 1 infection in children treated with highly active antiretroviral therapy. Navarro J; Resino S; Bellón JM; Abad ML; Gurbindo D; Fernández-Cruz E; Muñóz-Fernández MA AIDS Res Hum Retroviruses; 2001 Apr; 17(6):525-32. PubMed ID: 11350666 [TBL] [Abstract][Full Text] [Related]
7. Naïve and memory CD4+ T cells and T cell activation markers in HIV-1 infected children on HAART. Resino S; Navarro J; Bellón JM; Gurbindo D; León JA; Muñoz-Fernández MA Clin Exp Immunol; 2001 Aug; 125(2):266-73. PubMed ID: 11529919 [TBL] [Abstract][Full Text] [Related]
8. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. Lange CG; Lederman MM; Madero JS; Medvik K; Asaad R; Pacheko C; Carranza C; Valdez H J Acquir Immune Defic Syndr; 2002 May; 30(1):33-40. PubMed ID: 12048361 [TBL] [Abstract][Full Text] [Related]
9. Adrenaline-induced mobilization of T cells in HIV-infected patients. Søndergaard SR; Cozzi Lepri A; Ullum H; Wiis J; Hermann CK; Laursen SB; Qvist J; Gerstoft J; Skinhøj P; Pedersen BK Clin Exp Immunol; 2000 Jan; 119(1):115-22. PubMed ID: 10606972 [TBL] [Abstract][Full Text] [Related]
10. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. Gray CM; Schapiro JM; Winters MA; Merigan TC AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710 [TBL] [Abstract][Full Text] [Related]
11. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. Kaufmann GR; Zaunders JJ; Cunningham P; Kelleher AD; Grey P; Smith D; Carr A; Cooper DA AIDS; 2000 Dec; 14(17):2643-51. PubMed ID: 11125882 [TBL] [Abstract][Full Text] [Related]
12. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine. Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181 [TBL] [Abstract][Full Text] [Related]
13. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy. Benito JM; López M; Lozano S; Ballesteros C; Martinez P; González-Lahoz J; Soriano V J Acquir Immune Defic Syndr; 2005 Apr; 38(4):373-81. PubMed ID: 15764953 [TBL] [Abstract][Full Text] [Related]
14. Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA. Kaufmann GR; Zaunders JJ; Cunningham P; Cooper DA AIDS Res Hum Retroviruses; 1999 Jul; 15(11):963-72. PubMed ID: 10445808 [TBL] [Abstract][Full Text] [Related]
15. Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years. Arnó A; Ruiz L; Juan M; Zayat MK; Puig T; Balagué M; Romeu J; Pujol R; O'Brien WA; Clotet B AIDS; 1998 May; 12(7):697-704. PubMed ID: 9619800 [TBL] [Abstract][Full Text] [Related]
16. Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children. Resino S; Galán I; Bellón JM; Navarro ML; León JA; Muñoz-Fernandez MA J Clin Immunol; 2003 Jul; 23(4):279-89. PubMed ID: 12959220 [TBL] [Abstract][Full Text] [Related]
17. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. Bofill M; Mocroft A; Lipman M; Medina E; Borthwick NJ; Sabin CA; Timms A; Winter M; Baptista L; Johnson MA; Lee CA; Phillips AN; Janossy G AIDS; 1996 Jul; 10(8):827-34. PubMed ID: 8828739 [TBL] [Abstract][Full Text] [Related]
18. HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement. Lubaki NM; Shepherd ME; Brookmeyer RS; Hon H; Quinn TC; Kashamuka M; Johnson M; Gottle R; Devers J; Lederman HM; Bollinger RC J Acquir Immune Defic Syndr; 1999 Sep; 22(1):19-30. PubMed ID: 10534143 [TBL] [Abstract][Full Text] [Related]
19. Limited long-term naive CD4+ T cell reconstitution in patients experiencing viral load rebounds during HAART. Choremi-Papadopoulou H; Tsalimalma K; Dafni U; Dimitracopoulou A; Kordossis T J Med Virol; 2004 Jun; 73(2):235-43. PubMed ID: 15122798 [TBL] [Abstract][Full Text] [Related]
20. Maintenance of naive and Th1 CD4 phenotype and lack of CD8 activation in patients switching from protease inhibitors to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimens. Meroni L; Manganaro D; Varchetta S; Gatti N; Riva A; Monforte AD; Galli M J Acquir Immune Defic Syndr; 2001 Dec; 28(4):401-3. PubMed ID: 11707681 [No Abstract] [Full Text] [Related] [Next] [New Search]